$AMN

AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum?

AMN Healthcare Services' stock has surged 118.7% year-to-date, outperforming its industry and the S&P 500. Q2 revenues rose 2.3% to $673M, exceeding guidance, with adjusted EPS up 158% YoY. Growth is driven by strong demand in nurse and allied staffing, technology enhancements, and persistent healthcare workforce shortages. The company's 2026 EPS is projected to grow 127.9% to $3.10, with revenues expected to rise 20.9% to $3.30B.

Original reporting
Published Aug 24, 2026, 6:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 25, 2026, 6:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AMN Stock Rallies Nearly 119% YTD: What's Behind the Momentum? — source image
Decision brief

The 30-second read

$AMNNeutralLow
01

Why it matters

The article offers no new data; it reinforces existing bullish sentiment on AMN.

02

Market read

Provides a summary of AMN's recent performance; limited actionable insight for traders.

03

Timing

post‑quarter recap

Relevance 4/10Novelty 2/10Timing: post‑quarter recap

Background

Zacks analysis of AMN Healthcare's 118.7% YTD rally, Q2 performance, and growth drivers.

Company-level read

Ticker impact

$AMNNeutralHigh confidence
Context

Article recaps AMN Healthcare's Q2 results and recent stock rally, but provides no new earnings or guidance data.

Expected impact

Limited impact; traders likely already priced the rally.

Evidence & confidence

The article repeats known numbers without new disclosures.

Key entities

  • AMN Healthcare Services

    US‑listed staffing firm (ticker AMN) discussed as the primary subject.

Related articles

$AMNMed

AMN Healthcare Adds AI Interpreting as Prices Squeezed

AMN Healthcare reported Q2 2026 language services revenue of $69.6m, down 8% YoY due to pricing pressure. Overall revenue rose 2% to $673.2m, with net income at $21.2m. The company acquired Jaide Health for AI interpreting services and expects Q3 revenue of $640m-$655m.

$AMNMedAI 9/10

AMN Healthcare (AMN) Q2 2026 Earnings Call Transcript

AMN Healthcare reported Q2 2026 revenue of $673 million, up 2% year over year and 6% above the top end of guidance, with adjusted EPS of $0.77. Adjusted EBITDA was $73 million (10.9% margin) after $27 million in nonrecurring billing true-ups. Q3 revenue guidance is $640 million to $655 million. AMN also authorized share repurchases and acquired Jaide Health and ESSENTIAL.

$AMNMedAI 8/10

5 Revealing Analyst Questions From AMN Healthcare Services’s Q2 Earnings Call

AMN Healthcare Services reported Q2 revenue of $673.2 million, above analysts’ $628.2 million estimate, and adjusted EPS of $0.77 versus $0.19. Management attributed results to strong Nurse and Allied Solutions demand, including travel nurse and allied volumes, plus higher labor disruption revenue and improved search and international execution. Q3 revenue guidance midpoint was $647.5 million.

$AMNHighAI 9/10

AMN HEALTHCARE ANNOUNCES SECOND QUARTER 2026 RESULTS

AMN Healthcare Services (NYSE: AMN) reported Q2 2026 revenue of $673 million, up 2% year over year, and adjusted EBITDA of $73 million. GAAP net income was $21 million, or $0.53/share, and adjusted EPS was $0.77. The company said results exceeded guidance, citing travel nurse and allied growth, 27% search revenue growth, and acquisitions expanding AI and leadership offerings. Q3 revenue is expected 1-3% higher.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.